RecruitingNCT06317428
NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.
Change in Serum Levels of NT-proBNP During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.
Sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Enrollment
29 participants
Start Date
Jun 28, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.
Eligibility
Min Age: 50 Years
Inclusion Criteria2
- COPD;
- Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide;
Exclusion Criteria1
- Life expectancy less than one year;
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06317428
Related Trials
Home Hospital for Suddenly Ill Adults
NCT035242222 locations
Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis
NCT0724557612 locations
A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema
NCT070863392 locations
Effect of Telenursing on Oral Health
NCT074622211 location
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
NCT069749811 location